The Battle to Patent Your Genes
By Marcy Darnovsky and Jesse Reynolds,
The American Interest (September - October 2009)
| 08. 13. 2009
The Meaning of the Myriad Case
April 12, 1955 was a day of celebration. Across the United States, church bells rang, sirens blew, and people poured into the streets singing and dancing. The rejoicing was a spontaneous response to news that field trials of Jonas Salk's vaccine against the dread polio virus had been successful. The public had avidly followed the search for a vaccine for years. Hundreds of thousands of volunteers had participated in the trials, and tens of millions contributed dimes, quarters and dollars to the effort. According to a 1954 Gallup poll, more Americans knew about the polio field trials than knew the full name of their President, Dwight David Eisenhower.
On the day the field tests were pronounced a success, Edward R. Murrow interviewed Salk live on his television show See It Now. "Who owns the patent on this vaccine?" Murrow asked. "Well, the people, I would say", Salk replied. "There is no patent. Could you patent the sun?"
What a difference a half century makes. Today, patent applications are a part of the research routine, especially in the life sciences...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...